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Autosomal-dominant tubulo-interstitial kidney disease (ADTKD) encompasses a group of disorders characterized by renal tubular and
interstitial abnormalities, leading to slow progressive loss of kidney function requiring dialysis and kidney transplantation. Mutations
in UMOD,MUC1, and REN are responsible for many, but not all, cases of ADTKD.We report on two families with ADTKD and congenital
anemia accompanied by either intrauterine growth retardation or neutropenia. Ultrasound and kidney biopsy revealed small dysplastic
kidneys with cysts and tubular atrophy with secondary glomerular sclerosis, respectively. Exclusion of known ADTKD genes coupled
with linkage analysis, whole-exome sequencing, and targeted re-sequencing identified heterozygous missense variants in SEC61A1—
c.553A>G (p.Thr185Ala) and c.200T>G (p.Val67Gly)—both affecting functionally important and conserved residues in SEC61. Both
transiently expressed SEC6A1A variants are delocalized to the Golgi, a finding confirmed in a renal biopsy from an affected individual.
Suppression or CRISPR-mediated deletions of sec61al2 in zebrafish embryos induced convolution defects of the pronephric tubules but
not the pronephric ducts, consistent with the tubular atrophy observed in the affected individuals. HumanmRNA encoding either of the
two pathogenic alleles failed to rescue this phenotype as opposed to a complete rescue by humanwild-typemRNA. Taken together, these
findings provide a mechanism by which mutations in SEC61A1 lead to an autosomal-dominant syndromic form of progressive chronic
kidney disease. We highlight protein translocation defects across the endoplasmic reticulummembrane, the principal role of the SEC61
complex, as a contributory pathogenic mechanism for ADTKD.Introduction
Autosomal-dominant tubulo-interstitial kidney disease
(ADTKD) is a broad term that encompasses a group of
largely monosystemic disorders that typically lead to
progressive deterioration of kidney function and renal
failure.1 To date, mutations in three genes, REN (MIM:
613092), UMOD (MIM: 603860), and MUC1 (MIM:
174000), have been implicated in ADTKD,2 accounting
for the majority of affected individuals with ADTKD. De-
pending on the mutated gene involved, other phenotypes
have also been observed. Individuals with REN mutations
suffer from anemia, mild hyperkalaemia, and hyperurice-
mia due to a decreased renal urate excretion.3–7 Affected
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overlap also exists in individuals with mutations in TCF2
(MIM: 137920) encoding the transcription factor hepato-
cyte nuclear factor 1 (HNF1B), in whom hyperuricemia,
gout, and cystic kidney disease have been observed.8 In
contrast, families with MUC1 mutations have no other
clinical manifestations.9
Here we describe two families with ADTKD and congen-
ital anemia caused by missense mutations c.200T>G
(p.Val67Gly) and c.553A>G (p.Thr185Ala) in SEC61A1
(GenBank: NM_013336.3), encoding the alpha subunit of
the integral endoplasmatic reticular membrane translocon
SEC61. Taking advantage of its recently reported tertiary
structure, we demonstrate that p.Thr185Ala residue lies
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and the p.Val67Gly residue is located in the plug domain.
Since mutations in SEC61A1 have not been reported, to
date, in ADTKD, we transiently expressed both mutant
proteins in HEK293 cells. We found that both mutant
and wild-type SEC61A1 proteins are localized in the endo-
plasmic reticulum; however, the mutant was delocalized
partly to the Golgi. Likewise, SEC61A1 was abnormally ex-
pressed and localized in the Golgi also in a kidney biopsy
from an affected individual. We also performed in vivo as-
says to determine the role of SEC61A1 in the development
of the kidney. Knockdown or CRISPR-mediated deletions
of the human SEC61A1 ortholog, sec61al2, in zebrafish
perturbed the development of the pronephros leading to
an absence of convolution of the pronephric tubules, con-
firming that the SEC61 complex and its translocon func-
tion is necessary for normal renal development. Further,
in vivo complementation showed that both mutant
mRNAs failed to rescue the renal phenotype compared to
the observation of a complete rescue by the wild-type,
suggesting that both variants are pathogenic mutations.
Taken together, our data expand the genetic spectrum of
tubulo-interstitial kidney disorders and highlight a hith-
erto unknown role for SEC61A1 in the formation of the
minimal filtration unit of the kidney, the nephron.Material and Methods
Clinical Evaluation
Family 1 was ascertained by A.R., J.V.D.W., and B.L.L. at the Uni-
versity Hospital Ghent. Family 2 was ascertained by A.J.B. at the
Section on Nephrology, Wake Forest University School of Medi-
cine. Medical histories were obtained as a part of the affected
individual’s clinical workup. Investigations were approved by
the Institutional Review Boards of the participating centers and
were conducted according to the principles of the Declaration of
Helsinki. Karyotyping, array comparative genomic hybridization,
and fluorescent in situ hybridization for the velocardiofacial
syndrome were performed by standard methods.Genome-wide Linkage Analysis and Sequencing
Analysis
DNA was extracted by standard methods. 12 family members
(family 1) were genotyped using the Illumina Human CytoSNP12,
containing approximately 300,000 SNPs, according to the manu-
facturer’s guidelines (Illumina). Assuming complete penetrance
and dominant inheritance, we estimated power to detect linkage
via FastSLINK.10–12 The maximum LOD score encountered in
simulation replicates was 2.71. Multipoint parametric linkage
analysis was carried out with Merlin13 using a subset of 10,521
SNPs, with an average inter-marker spacing of 250 kb.
Whole-exome sequencing was performed using the 50 Mb
SureSelect Enrichment Kit (Agilent Technologies) for enrichment
followed by next-generation sequencing on a SOLiD 4 (Life Tech-
nologies). The resulting data were analyzed using an in-house
analysis pipeline for variant identification and interpretation
(Radboud University Medical Center).14–19
A custom gene panel was designed to target coding regions
(6.88 Mb) of 3,616 genes associated with known inherited meta-The Abolic diseases, all known genes encoding mitochondrial proteins,
all OMIM genes with known phenotype, and a set of genes causing
nephrologic (including SEC61A1) and neurologic diseases. DNA
enrichment was performed using the Nimblegen SeqCap EZ
Choice Library kit (Roche) according to the manufacturer’s proto-
col. DNA sequencing was performed on the captured barcoded
DNA library via an Illumina Hiseq 1500 system. The resulting
FASTQ files were aligned to the human Genome Reference
(hg19) via Novoalign (3.02.10). After genome alignment, conver-
sion of SAM format to BAM and duplicate removal were performed
using Picard Tools (1.129). The Genome Analysis Toolkit, GATK
(3.3),20–22 was used for local realignment around indels, base reca-
libration, and variant recalibration and genotyping. Variant anno-
tation was performed with SnpEff23 and GEMINI.24
The SEC61A1 and the NPHP3 (MIM: 267010, 604387) candidate
causal variants were amplified using the primers listed in Table S1
and standard PCR conditions. PCR products were bi-directionally
sequenced using the BigDye Terminator Cycle Sequencing
kit (Applied Biosystems) and separated on an ABI 3130XL
Genetic Analyzer (Applied Biosystems). Sequence numbering for
SEC61A1 is based on Ensembl transcript ENST00000243253, with
the A nucleotide of the start codon ATG indicated as position þ1.Immunohistochemistry of Kidney Biopsies
Paraformaldehyde-fixed kidney biopsies of family members 1-II:3
and 1-III:5 were investigated. Immunodetections of UMOD, REN,
and MUC1 were performed as previously described.3,9,25 URAT-1
was detected with rabbit polyclonal SLC22A12 antibody (Sigma-
Aldrich cat# HPA024575, RRID: AB_1858650) diluted 1:25 in 5%
BSA in PBS. SEC61A1 was detected with rabbit recombinant
monoclonal SEC61A antibody (EPR14379) (ab183046, Abcam)
diluted 1:100 in 5% BSA in PBS. The sections were incubated
with primary antibodies overnight at 4C. Detection of bound pri-
mary antibody was achieved using Dako EnVision þ TM Peroxi-
dase Rabbit Kit (DAKO) with 3,30-diaminobenzidine as substrate.Transient Transfection of SEC61A1 in Human
Embryonic Kidney 293 Cells
Wild-type SEC61A1 cDNA was synthesized by GenScript. A single
C-terminal flag-tag sequence was appended to the originally syn-
thesized wild-type cDNA using polymerase chain reaction (PCR)
with specific oligonucleotide primers. Resulting PCR product was
cloned into pCR3.1 vector (Invitrogen) and introduced into the
Escherichia coli TOP 100F strain (Invitrogen). The wild-type
SEC61A1-flag clones (SEC61A1_FLAG/wt) were selected by
sequencing. Mutant constructs c.553A>G (SEC61A1_FLAG
/185A) and c.200T>G (SEC61A1_FLAG /67G) were prepared by
site-directed mutagenesis. HEK293 cells were maintained in
DMEM High Glucose medium supplemented with 10% (vol/vol)
fetal calf serum (PAA), 100 U/mL penicillin G (Sigma), and
100 mg/mL streptomycin sulfate (PAA Laboratories GmbH). Trans-
fections were carried out using Lipofectamine 2000TM (Invitro-
gen) with either 1.5 mg or 4 mg DNA for 1.5 3 105 or 8 3 105 cells,
respectively. Expression of SEC61A1_FLAG proteins was assessed
by standard western blot analysis with mouse monoclonal anti-
FLAG antibody (F1804, Sigma-Aldrich). Endogenously expressed
SEC61A1, SEC61B, and tubulin were detected with rabbit mono-
clonal Anti-SEC61A antibody (ab183046, Abcam), rabbit
polyclonal anti-SEC61B antibody (ABIN2707013, Antibodies On-
line), and mouse monoclonal anti-acetylated tubulin antibody
(Sigma-Aldrich cat# T7451; RRID: AB_609894), respectively. Goatmerican Journal of Human Genetics 99, 174–187, July 7, 2016 175
anti-rabbit IgG (Thermo) and goat anti-mouse IgG (Sigma) were
used as secondary antibodies. Chemiluminiscent signal for
SEC61B and SEC61A1-FLAG detection was generated using Super
Signal West Femto (Pierce). Super Signal West Pico (BioRad) was
used for detection of SEC61A and acetylated tubulin. Correspond-
ing band intensities were measured by GeneTools (Syngene) and
normalized to acetylated tubulin. The measurements were per-
formed at 36 hr after transfection in three biological replicates.
Intracellular Localization of SEC61A1 in Transiently
Transfected HEK Cells and Kidney Biopsies
For immunofluorescence labeling, the transfected cells were
grown on 1.8 cm2 glass 4-chamber slides (BD Falcon) for 24 hr.
The cells were fixed with 100% ice cold methanol for 10 min in
20C, washed, blocked with 5% BSA in PBS, and incubated in a
humidified chamber at 4C overnight with one of the following
antibodies: the mouse monoclonal anti-FLAG M2 antibody
(Sigma-Aldrich cat# F1804; RRID: AB_262044) for SEC61A1_FLAG
detection, the rabbit polyclonal anti-PDI antibody (Cell Signaling
cat# 3501; RRID: AB_2156433) for endoplasmic reticulum detec-
tion, the rabbit polyclonal anti-GM130 antibody (Sigma-Aldrich
cat# G7295; RRID: AB_532244) for Golgi detection, and the rabbit
polyclonal pan Cadherin antibody (Abcam cat# ab6529; RRID:
AB_305545) for plasma membrane detection.
For intracellular localization in kidney biopsies, SEC61A1 was
detected with rabbit recombinant monoclonal SEC61A antibody
as described above. The Golgi was detected with mouse mono-
clonal anti Golgi 58K Protein/Formiminotransferase Cyclo-
deaminase (FTCD) antibody (Sigma-Aldrich cat# G2404; RRID:
AB_477002). Endoplasmic reticulumwas detected with the mouse
monoclonal anti-PDI antibody (Enzo Life Sciences cat# ADI-SPA-
891; RRID: AB_10615355).
For fluorescence detection, species-specific secondary antibodies
Alexa Fluor 488 or 555 (Molecular Probes, Invitrogen) were used.
Slides were mounted in the fluorescence mounting medium
ProLong Gold Antifade Mountant with DAPI (Molecular Probes,
Invitrogen) and analyzed by confocal microscopy. XYZ images
were sampled according to Nyquist criterion using a Leica SP8X
laser scanning confocal microscope, HC PL Apo objective (633,
N.A.1.40), 405 nm diode/50 mW DMOD Flexibl, and 488 and
555 laser lines in 470–670 nm 80 MHz pulse continuum WLL2.
Images were restored using a classic maximum likelihood restora-
tion algorithm in the Huygens Professional Software (SVI). The
colocalization maps employing single pixel overlap coefficient
values ranging from 0 to 1 were created in the Huygens Profes-
sional Software. The resulting overlap coefficient values are
presented as the pseudo color whose scale is shown in the corre-
sponding lookup tables (LUT).
Structural Impact of Identified Mutations
Mutations were mapped into the recently resolved 3D structure of
Sec6126 determined in various states, namely, Sec61 complex
translating hydrophilic peptide (PDB: 4CG5), translating peptide
being inserted into membrane (PDB: 4CG6), and an idle protein
complex (PDB: 4CG7). Structural models were visualized with
Pymol Viewer (DeLano Scientific).
Knockdown, Rescue Experiments, Immunostaining,
and Embryo Manipulations
Zebrafish (Danio rerio) embryos were raised and maintained as
described.27 A splice-blocking morpholino (MO) against the176 The American Journal of Human Genetics 99, 174–187, July 7, 20fourth exon-intron junction of sec61al2: (50-TGCTCATTCAGTAG
TACACACCTCT-30) was designed and obtained from Gene Tools.
We injected 4 ng of MO and/or 100 pg RNA into wild-type zebra-
fish embryos at the 1- to 2-cell stage. Injected embryos were scored
at 4 days post-fertilization (dpf) and classified into three groups—
normal, V-shaped, and straight—based on the phenotype
compared with an age-matched control group from the same
clutch. For wild-type andmutant rescue experiments, site-directed
mutagenesis was performed to introduce the variants into the
mouse wild-type sec61a1 transcript (100% identity with the hu-
man transcript at the protein level). Wild-type and mutant full-
length messages were Sanger sequenced and were cloned into
the pCS2 vector and transcribed in vitro using the SP6 Message
Machine kit (Ambion). All the experiments were repeated three
times, and a chi-square test was used to determine significance.
Suppression of endogenous message was shown by PCR amplifica-
tion of cDNA reverse transcribed from extracted total mRNA
(primers available upon request). Whole-mount immunostaining
with the anti-Naþ/Kþ ATPase alpha-1 subunit antibody (a6F;
DSHB) was performed for examining pronephric tubules and
ducts. Embryos were fixed in Dent’s fixative (80% methanol,
20% dimethylsulphoxide [DMSO]) overnight. After rehydration
with decreasing series of methanol in PBS, embryos were washed
with PBS, permeabilized with 10 mg/mL proteinase K, and post-
fixedwith 4% PFA. Embryos were thenwashed twice with IF buffer
(0.1% Tween-20, 1% BSA in 13 PBS) for 10 min at room tempera-
ture. After incubation in blocking solution (10% FBS, 1% BSA in
13 PBS) for 1 hr at room temperature, embryos were incubated
with the anti-a6F antibody (1:20) in blocking solution overnight
at 4C. After two washes in IF buffer for 10 min each, embryos
were incubated in the secondary antibody solution, 1:1,000 Alexa
Fluor rabbit anti-mouse IgG (Invitrogen), in blocking solution for
1 hr at room temperature.
Plasmids and Generation of sec61al2 Guide RNAs
The pT7-gRNAwere generated by the W. Chen lab28 and obtained
from Addgene (Addgene plasmid numbers 46759). Guide RNA
(gRNA) was designed to target exon 4 of sec61al2 utilizing the
CHOP CHOP design tool. Oligonucleotides were annealed and
cloned into the pT7-gRNA vector digested by BsmBI: sec61al2-
gRNA2, 50-GTGATCATGGCATCCAACAG-30 and 50-CTGTTGG
ATGCCATGATCAC-30. For making gRNA, template DNA was line-
arized with BamHI and gRNA was generated by in vitro trans-
cription using MEGAshortscript T7 kit (Invitrogen). To test the
efficiency of the gRNA, a mix of gRNA (100 ng) and purified
CAS9 protein (PNABio, cat# CP01) was injected directly into 100
1-cell-stage embryos. We phenotyped three independent clutches.
To observe directly genetic editing mediated by our gRNA2 s61al2-
CRISPR/Cas9 system in injected embryos (founders, F0), genomic
DNA was prepared from 30 randomly selected individuals and a
short stretch of DNA (exon 4 of zebrafish sec61al2) flanking the
target site was PCR amplified from the genomic DNA. A T7 endo-
nuclease I (T7EI) assay was then performed as described28 followed
by Sanger sequencing; the percentage of mosaicism was estimated
at ~50% in the F0 population.Results
Clinical Investigations
A three-generation family (family 1; Figure 1A) presented
with autosomal-dominant progressive chronic kidney16
Figure 1. Pedigrees, Schematic Protein Representation, and Conservation of SEC61A1
(A) Circles indicate women, squares indicate males; filled symbols indicate affected individuals; plus sign indicates presence of SEC61A1
variation; minus sign indicates absence of SEC61A1 variation.
(B) Position of the p.Val67Gly change in the plug region and the p.Thr185Ala change in the fifth transmembrane region of the trans-
locase-transmembrane domain of SEC61A1.
(C) Conservation of the Val67 and Thr185 amino acids throughout evolution.disease associated with congenital anemia and intrauterine
and postnatal growth retardation (Table 1). At term, birth
weights ranged from 1,800 to 2,400 g (normal range
2,700–4,600 g). Variable findings on physical examination
included cleft palate or bifid uvula (1-I:2 and 1-II:6), velo-
pharyngeal insufficiency (1-II:6), pre-axial polydactyly
(1-II:6), and mild cognitive impairment (1-II:1, 1-II:3,
1-II:5, and 1-II:6). Blood pressures were consistently in
the normal range. Significant laboratory findings included
normochromic, normocytic anemia that was responsive to
erythropoietin, elevated serum creatinine levels, mild
hyperuricemia, and the absence of proteinuria. Hemato-
logical and biochemical parameters for the three youngest
affected individuals (1-III:4, 1-III:5, 1-III:7) are summarized
in Table 1. Affected individuals 1-III:4 and 1-III:7 were lost
to follow-up.
The proband (1-III:5) presented at 12 years with height
of 132 cm (< P3). Physical exam was otherwise unre-
markable. Laboratory studies revealed a serum creatinine
concentration of 1.46 mg/dL, blood urea nitrogen concen-
tration of 93 mg/dL, and serum uric acid level of 6.7 mg/dL
at last follow-up. The fractional excretion rates of sodium
and uric acid were normal and the urinary potassium/The A(urinary potassium þ sodium) ratio was low. Renin
(5–14 pcg/mL) and aldosterone (5–14 ng/dL) were always
in the low normal range. There was no hematuria or
proteinuria. Ultrasound examinations revealed small,
dysplastic kidneys without cysts.
At the age of 53 years, individual 1-II:1 has a serum creat-
inine concentration of 1.96 mg/dL, blood urea nitrogen
level of 109.6 mg/dL, and estimated glomerular filtration
rate (eGFR) of 27 mL/min/1.73 m2. She has a normal
hemoglobin level (12.7 g/dL) under erythropoietin treat-
ment. No proteinuria or hematuria was detected. Blood
pressure was borderline 150/80 mmHg. She measured
147 cm for a weight of 63 kg. Affected individual 1-I:2
died at the age of 73 years while being on dialysis. She
was admitted with acute sepsis (CRP 112 mg/L), lung
edema, and kidney failure (creatinine 5.13 mg/dL). No
gout or neutropenia was observed in family 1.
Kidney biopsies of family members 1-II:3 and 1-III:5
revealed multiple small foci of tubulo-interstitial lesions:
clusters of atrophic tubules, either featured by thickened
tubular basement membranes or those of endocrine type,
occasionally protein casts in tubular lumina and discrete
interstitial fibrosis (Figure 2A). Glomerular changes weremerican Journal of Human Genetics 99, 174–187, July 7, 2016 177
Table 1. Clinical, Hematological, Biochemical, and Genetic Investigation
Individual 1-III:4 1-III:5 1-III:7 2-III:1 2-II:2 Unit Reference Value
Age at investigation 11 8 4 27 61
Hematology
Leukocytes 8.45 8.4 7.89 3.4 3.5 103/mL 4.5–13.5
Hemoglobin 10.3 10 9.1 9.5 12.3 g/dL 11.5–15.5
Hematocrit 32.5 29.6 27.9 28.7 36.9 % 35.0–45.0
Biochemistry
Ureum 39.2 36.9 42.9 47 42 mg/dL 13–43
Creatinin 1.20 1.17 0.9 1.65 2.6 mg/dL 0.53–0.79
Uric acid 9.0 6.9 5.6 7.8 5.8a mg/dL 3.4–7.0
eGFR 52.2
Other characteristics
Birth weight 2,220 2,400 1,800 3,430 g
Birth length 45 47 45 cm
Onset nephropathy 11 1 4 18 year
Current weight P3 P3 P50
Current length P10 <P3 P25
Abbreviations are as follows: eGFR, estimated glomerular filtration; P, percentile
aIndividual with a history of hyperuricemia; value obtained while on allopurinol.dominated by cystic dilatation of Bowmann’s spaces with
collapsed or rudimentary glomerular tufts and often filled
with precipitate of plasma proteins (Figure 2B). Focal peri-
glomerular fibrosis and focal glomerular sclerosis, arterial
intimal thickening, and luminal narrowing of blood
vessels were present. Cytogenetic analyses on affected
individual 1-III:5, including both karyotyping and
22q11-fluorescent in situ hybridization, to exclude veloc-
ardiofacial syndrome, revealed normal results. In addition,
whole-genome microarray analysis did not reveal any sub-
chromosomal deletions or duplications.
Family 2 was referred for evaluation of ADTKD occur-
ring in the father and daughter, but no involvement
of other affected family members (Figure 1A). Both
affected relatives suffered from congenital anemia
and neutropenia, gout in the second decade of life, and
chronic kidney disease. They had normal growth
and intelligence.
The proband 2-III:1 presented at 2 weeks of age, when
she was admitted for an abscess on the right buttock. The
white blood count at that time was 14.3 3 109/L with
4% neutrophils, 92% lymphocytes, and 4% monocytes.
The affected individual had persistent granulocyte stimu-
lating factor-unresponsive neutropenia and recurrent
admissions for cutaneous abscesses. Although the neutro-
penia persisted, infections were no longer present after
age 12. The affected individual developed gout at age 18
years, with a serum urate of 7.2 mg/dL and serum creati-
nine of 1.1 mg/dL (eGFR 73 mL/min/1.73 m2). At age 28,
she was diagnosed with hypotension (systolic blood pres-178 The American Journal of Human Genetics 99, 174–187, July 7, 20sure readings in the high 80s) and hyperkalemia (serum
potassium 5.7 mEq/L). There was no proteinuria or hema-
turia. The plasma renin activity was 1.0 ng/mL/hr (normal
range 0.5–5.9 ng/mL/hr), and the serum aldosterone level
was 9.0 ng/dL (normal range 5–80 ng/dL). She was treated
with fludrocortisone. Renal ultrasound showed the left
kidney to be 9 cm and right kidney 9.4 cmwith hyperecho-
genic parenchyma.
The father (2-II:2) also suffered from cutaneous ab-
scesses requiring hospitalization until age 12 years. He
demonstrated anemia and neutropenia. A bone marrow
biopsy performed at age 12 showed a decrease in normo-
blasts and white blood cell precursors with normal mega-
karyocytes. Gout was diagnosed at age 21, and the
affected individual presented for evaluation of chronic
kidney disease at 51 years with a serum creatinine of
1.4 mg/dL (eGFR 58 mL/min/1.73 m2). Over 10 years
the serum creatinine increased to 2.8 mg/dL (eGFR
23 mL/min/1.73 m2). Renal ultrasound revealed that
the right kidney is 11.6 cm and the left 13.9 cm, with
multiple bilateral simple cysts throughout the kidney.
Urinary uromodulin was decreased in both individuals
(Figure S1).
Molecular Genetic Analysis
Linkage Analysis and Whole-Exome Sequencing in Family 1
Based on the phenotypic similarities between the clinical
presentation of family 1 and individuals with REN muta-
tions (early-onset anemia, hyperuricemia, and progressive
kidney failure), we first excluded REN in the proband16
Figure 2. Kidney Biopsy from Individual
1-II:3 with the p.Thr185Ala Substitution
(A) Clusters of atrophic tubules surround-
ing glomeruli with collapsed or rudimen-
tary capillary tufts (marked by asterisks).
A part of affected tubules shows thickening
of tubular basement membranes; the re-
maining are endocrine-type atrophic tu-
bules with narrowed lumina and simplified
epithelium. PAS staining.
(B) Prominent cystic dilatation of Bow-
mann’s spaces (marked by asterisks), which
are sometimes filled with finely granular
proteinaceous material. PAS staining.
(C andD) SEC61A protein was detected im-
munohistochemically in proximal tubules
(PT) and distal tubules (DT) in kidney tis-
sue in both affected individual (C) and a
control subject (D). Compare coarsely
granular intracytoplasmic staining in the
affected individual with finely granular
and less intensive pattern in the control
subject.
(E) Renin was undetectable immunohisto-
chemically in juxtaglomerular apparatus
(marked by arrows) in an affected individ-
ual but weak finely granular staining was
found in the cytoplasm of renal tubules.
(F) Comparison with strong renin positiv-
ity in juxtaglomerular apparatus and nega-
tivity in tubular epithelium in a control
subject.
Scale bars represent 100 mm in (A) and (B),
30 mm in (C) and (D), and 50 mm in (E)
and (F).(1-III:5) by Sanger sequencing. Subsequently, we collected
DNA from 12 family members, including 7 affected indi-
viduals, and performed genome-wide multipoint para-
metric linkage analysis using SNP microarrays. Under a
dominant model of inheritance, we identified a candidate
region with a maximum LOD score of 2.7 on chromo-
some 3q14-25.1 (Figure S2). The region was confirmed
by microsatellite marker analysis (between markers
D3S3513 and D3S1299; results not shown). This 32-Mb
candidate region (genomic positions: 120M–152M; NCBI
build 37 [hg 19]) was gene rich with a total of 357
annotated genes. We next performed whole-exome
sequencing on the proband and focused on rare (<1%
minor allele frequency in the general population) and
non-synonymous coding changes within the critical in-
terval. We found two heterozygous nucleotide changes
within the linked region on chromosome 3: c.1189C>T
(p.Arg397Cys) in exon 7 of NPHP3 and c.553A>G
(p.Thr185Ala) in exon 7 of SEC61A1. The former did
not segregate with the disease in the family whereas the
latter did (Figure 1A). The Thr185 position is conserved at
the nucleotide (PhyloP score: 4.95) and amino acid levels
(Figure 1C). The variant was predicted to be pathogenic
by two prediction tools, SIFT29 and MutationTaster,30The Aalthough it was benign according to PolyPhen.31 In
addition, the variant was absent from the 1000 Genomes
Project database,32 the Exome Variant Server, the ExAC
database, a series of 204 Belgian control chromosomes,
and internal exome databases curated in Prague (~600
exomes and 140 custom gene panels) and Nijmegen
(~500 exomes).
Screening for SEC61A1 Mutations in Individuals with a Similar
Phenotype
The second SEC61A1 variant was identified in 1 out of 46
unrelated probands with an ADTKD-like phenotype
using a custom gene panel sequencing developed at the
Institute for Inherited Metabolic Disorders in Prague.
The proband from family 2 carried a heterozygous
missense variant c.200T>G (p.Val67Gly) in SEC61A1.
The variant is also conserved at the nucleotide (PhyloP
score: 6.32) and amino acid levels (Figure 1C). The
variant was also predicted to be damaging by SIFT and
PolyPhen and disease causing by MutationTaster. The
p.Val67Gly change was reported once in the ExAC
database (1/121,410 alleles) and was absent from all
other databases mentioned above. Co-segregation of
the p.Val67Gly change in the family was confirmed by
Sanger sequencing (Figure 1A).merican Journal of Human Genetics 99, 174–187, July 7, 2016 179
Figure 3. Structural Topology of the
Mutations in Sec61
The cryo-EM based models of translocons
translating hydrophilic peptide with
opened pore (PDB: 4CG5) and translating
peptide inserted to membrane possessing
a pore sealed by a plug domain (PDB:
4CG6) were used for illustration. Regions
containing mutations are depicted with
cartoon representation, namely plug
domain (p.Val67Gly) in magenta and
TM5 (p.Thr185Val) in orange. Mutated
residues are highlighted as dots and/or
sticks.
(A) Overall structure of Sec61 and location
of the mutated residues.
(B) Orientation of the mutated residues in
the Sec61 structure with opened transloca-
tion pore (left) and with pore sealed by a
plug domain (right).
(C) Left: constriction ring formed by apolar
residues represented by green (TM2, TM7,
and TM10) and orange (positioned at
TM5 near Thr185 residue) spheres;
mutated residues are shown as red spheres.
Right: detail of TM5 illustrating hydrogen
bonding of hydroxyl Thr185 with car-
bonyls of Leu181 and Phe182.Prediction of the Structural and Functional Impact of the
SEC61A1 Mutations
SEC61A1 encodes the protein transport protein Sec61 sub-
unit alpha isoform 1 (SEC61a) that assembles with the pro-
tein transport protein Sec61 subunit beta (SEC61b) and the
protein transport protein Sec61 subunit gamma (SEC61g)
to form the heterotrimeric protein-conducting channel
SEC61 that is a part of the mammalian ER translocon.
The Thr185 residue lies in the transmembrane helix 5
(TM5) that is located in the vicinity of translocated pep-
tides.33 Residues Ile179 and Ile183 are involved in the for-
mation of the constriction ring within a pore of the SEC61.
As such, the mutation p.Thr185Ala is likely to disrupt the
intrahelical hydrogen bond between the Thr185 side chain
and the carbonyls of Leu181 and Phe182 and thus affects
the structural integrity of the channel.34 Structural map-
ping of Val67 showed that this residue is located directly
in the translocon pore and is part of a plug domain that
seals and stabilizes the pore during the closed state
(Figure 3). The increased flexibility of the glycine residue
in this positionmay destabilize the pore structure and alter
ion permeability of the channel, affecting translocation ef-
ficiency and/or inducing abnormal signal peptide orienta-
tion. A similar effect on the post-translational modification
and sorting of secretory and transmembrane proteins has
been described for the neighboring Arg66 residue in
SEC61A1.35,36 Systematic mutagenesis of the conserved
and charged residues forming the constriction ring and
plug domain in bacteria and yeast demonstrated that these
alterations had no effect on translocon functionality and180 The American Journal of Human Genetics 99, 174–187, July 7, 20cell viability but affected translocation efficiency, integra-
tion of hydrophobic sequences into lipid bilayers, and sta-
bility of the translocon in the closed state.37,38
Immunohistochemical Analysis of SEC61A1 in
Kidney Biopsies
To assess the effect of identified mutations on the expres-
sion of SEC61A1, we performed immunohistochemical
analysis of a kidney biopsy obtained from family mem-
ber 1-II:3 with the p.Thr185Ala substitution. We
observed a strong coarsely granular cytoplasmic staining
in proximal and distal tubules and collecting ducts
(Figure 2C). Upon comparison to the finely granular
and less intensive intracellular staining observed in
control subjects (Figure 2D), this was suggestive of
abnormal intracellular localization and/or aggregation
of SEC61A1.
Given that translocon malfunction may affect cotra-
nslational translocation, post-translational processing,
and cellular trafficking of secretory and transmembrane
proteins, we also performed immunohistochemical anal-
ysis of renin, uromodulin, mucin-1, and urate transporter
SLC22A12. In the affected kidney, we observed absence of
renin staining in juxtaglomerular granular cells, which
was accompanied by mild granular positivity of renin
staining in the cytoplasm of tubular cells (Figure 2E). This
observation was similar to that made in renal tissue from
individuals with REN mutations.3 Expression patterns of
the other proteins were comparable with controls
(Figure S3). Atrophic cortical tubules were predominantly16
Figure 4. Transient Expression and Intracellular Localization of SEC61A1_FLAG Variants in Human Embryonic Kidney 293 Cells
(A) Western blot detection of transiently expressed wild-type and mutated SEC61A1_FLAG proteins and endogenously expressed
SEC61A, SEC61B, and tubulin at 36 hr post-transfection.
(B) Quantitative image analysis of wild-type and mutated SEC61A1_FLAG proteins demonstrating decreased amounts of mutated pro-
teins compared to the wild-type. Results representmeans of fold change5 SD of the relative signal intensities of mutated proteins to the
wild-type protein from three biological replicates. Signal intensities of SEC61A1_FLAG proteins were normalized to that of a-tubulin.
Statistical significance was assessed using Student’s t test; *p < 0.05; **p < 0.01; ***p < 0.001.
(C) Quantitative image analysis of the endogenously expressed SEC61A and SEC61B demonstrating that overexpression of neither pro-
tein significantly affected relative amounts of the endogeneously expressed SEC61A1 and SEC61B transient expression of SEC61A1. Re-
sults represent means of fold change5 SD from three biological replicates of the relative signal intensities of SE61A over SEC61B in cells
expressing individual mutated SEC61A1_FLAG protein and empty vector compare to that of cells expressing the wild-type protein.
Signal intensities of SEC61A and SEC61B were normalized to that of a-tubulin. Statistical significance was assessed using Student’s t test.
(D) Immunofluorescence analysis showing that the wild-type SEC61A1_FLAG is present in a finely granular (subpanel A) or coarsely
granular (subpanel D) structures. Co-staining of wt-SEC61A1_FLAG with Golgi matrix protein GM130 (subpanel B) and with Protein
disulphide isomerase (PDI) (subpanel E), a marker of endoplasmic reticulum (ER), demonstrating absence of the wt-SEC61A1_FLAG
in the Golgi (subpanel C) but presence in the ER (subpanel F). p.Val67Gly (subpanels G and J) and p.Thr185Ala (subpanels M and P)
variants of SEC61A1_FLAG are present in a form of intracellular clumps that are more pronounced in the latter. Co-staining with
GM130 (subpanels H and N) and PDI (subpanels K and Q) demonstrating localization of both mutant proteins in the Golgi (subpanels
I and O) as well as in ER (subpanels L and R). The degree of SEC6A1A_FLAG colocalization with selected markers is demonstrated by the
fluorescent signal overlap coefficient values that range from 0 to 1. The resulting overlap coefficient values are presented as the pseudo
color which scale is shown in corresponding lookup table.MUC1andpartiallyUMODpositive, suggesting their origin
in distal tubules and collecting ducts in kidney biopsy.
Intracellular Localization of SEC61A1 Variants in
Human Embryonic Kidney Cells and Kidney Biopsies
To determine their production, stability, and intracellular
localization, we transiently expressed wild-type SEC61A1The A(SEC61A1_FLAG/wt) and both mutant proteins (SEC61A1_
FLAG /185A, SEC61A1_FLAG /67G) in HEK293 cells. Quan-
titative western blot analysis demonstrated that, compared
to wild-type protein, production of the SEC61A1_FLAG/
67G and SEC61A1_FLAG/185A is decreased significantly
(Figures 4A and 4B). Overexpression of neither protein
affected relative amounts of the endogeneously expressedmerican Journal of Human Genetics 99, 174–187, July 7, 2016 181
Figure 5. Intracellular Localization of SEC61A1 in Affected Kidney
(A and D) In affected kidney, SEC61A1 is present in coarsely granular structures.
(B, C, E, and F) Co-staining of SEC61A1 with Protein disulphide isomerase (PDI) (B), a marker of endoplasmic reticulum (ER), and with
58k Golgi-protein (E) demonstrate localization of the SEC61A1 in the ER (C) and in the Golgi (F).
(G and J) In control kidney, SEC6A1A is present in finely granular structures.
(H, I, K, andL)Co-stainingwith (H)PDIand (K)GM130demonstrating localizationof SEC61A1 inER (I) butnot in theGolgi (L). Thedegree
of SEC6A1A colocalization with selected markers is demonstrated by the fluorescent signal overlap coefficient values that ranging from
0 to 1. The resulting overlap coefficient values are presented as the pseudo color which scale is shown in corresponding lookup table.SEC61A1 and SEC61B (Figure 4C). Immunofluorescence
analysis and colocalization studies showed that wild-type
protein was present in finely granular structures that were
localized exclusively in the ER (Figure 4D). Bothmutant pro-
teins formed intracellular clumps localized in the ER
(Figure 4D, panels I and R) and partly also in the Golgi
(Figure 4D, panels I and O and in more detail in Figure S4).
To test the relevance of these findings in the setting of
the tissue from the affected individual, we compared the
intracellular localization of SEC61A1 in control and
affected kidney obtained from family member 1-II:3
with p.Thr185Ala substitution. In the affected kidney,
SEC61A1 is present in coarsely granular structures (Figures
5A and 5D). SEC61A1 was localized in the ER (Figure 5C)
and a significant proportion of the protein was also local-
ized in the Golgi (Figure 5F and in more detail in
Figure S5). In contrast, in control kidney sections,
SEC61A1 was present in finely granular structures (Figures
5G and 5J) and was located exclusively in the ER
(Figure 5I).
The presence of the mutant SEC1A1 proteins in the
Golgi thus suggests that these proteins are recognized as
abnormal and as such they are probably dislocated to the
ER-Golgi intermediate compartment (ERGIC) and sub-
jected to endoplasmic-reticulum-associated protein de-
gradation (ERAD).39
Functional Testing of SEC61A1 Variants in Zebrafish
Embryos
Our genetic data, the in silico analysis of the effect of the
variants on the structure of SEC61A1, and the abnormal
intracellular localization of the mutant proteins suggested182 The American Journal of Human Genetics 99, 174–187, July 7, 20that mutations in SEC61A1 is a strong candidate for the
dominant familial nephropathy in both pedigrees. To our
knowledge, mutations in SEC61A1 have not yet been asso-
ciated with renal phenotypes in humans, nor has it been
known to be necessary for the development of the kidney.
Thus, we sought to determine the pathogenicity of the var-
iants in vivo. Some of the pathologies observed in the
affected individuals, such as fibrosis and gout, cannot be
modeled reliably in early development. However, the
structure of the nephron is conserved between human
and zebrafish and one of the common features among
affected individuals is tubular atrophy.40 Therefore, we
asked whether SEC61A1 is involved in the development
of the pronephros by suppressing the zebrafish ortholog
of SEC61A1 and examining the complete system of paired
pronephric tubules and ducts at 4 days post-fertilization
(dpf).
Using reciprocal BLAST, we identified a single Danio rerio
SEC61A1 ortholog (sec61al2 on chromosome 6; 96%amino
acid identity). We designed a splice-blocking morpholino
(sbMO), targeting the splice donor site of exon 4, which
we injected into zebrafish eggs. Reverse-transcription poly-
merase chain reaction (RT-PCR) demonstrated that the
sbMOaffected the correct splicing of the sec61al2 transcript
(i.e., skipping of exon 4; Figure S6). To test whether sec61a1
suppression affects the development of the pronephros, we
stained the sbMO-injected embryos with an anti-Naþ/Kþ
ATPase alpha-subunit monoclonal antibody (a6F), an
enzyme expressed by the epithelial cells in the pronephric
tubules and ducts.41 The embryos were scored and binned
into three categories: normal convolution of the proneph-
ric tubules, V-shaped (partial convolution of the tubules),16
Figure 6. Suppression of SEC61A1 Leads to Pronephric Tubular Atrophy in Zebrafish
(A–C) Whole-mount immunostaining of 4 days post-fertilization (dpf) zebrafish larvae with anti-Naþ/Kþ-ATPase alpha subunit mono-
clonal antibody (a6F) shows the overall anatomy of the pronephric ducts (pd) and pronephric tubules (pt), which become progressively
convoluted in control larvae. Three levels of convolutionwere assessed: convoluted (normal) (A and A0), V-shaped (B and B0), and straight
pronephric tubule (C and C0). The pronephric ducts are normal.
(D) Qualitative scoring of the tubular atrophy was performed in larvae batches injected with sec61al2 MO alone; MO and mutant
(p.Thr185Ala) RNA or (p.Val67Gly) RNA; MO and wild-type (WT) capped-RNA; WT and mutant RNAs alone; and control.
(E) Results of Fisher’s exact test conducted between pairs of conditions. The significant p values (< 0.05) are highlighted in red.or straight (absence of tubular convolution) (Figures 6A–
6C). Masked scoring of embryos at 4 dpf (60 embryos on
average per condition, repeated three times) showed an
overall percentageof 70%of affected embryos that included
30% with an absence of convolution of the pronephric
tubules and 40% with partial convolution (Figure 6D). By
contrast, the pronephric ducts were extended along the
trunk indistinguishably from control embryos (Figures
6A–6C). The tubular atrophy observed in the sec61al2mor-
phants was unlikely to be driven by overall developmental
delay; morphants had a normal appearance with regard to
their pigment cells and head size. In addition, there was
no appreciable pathology in other internal organs, such as
the heart or the swim bladder. Finally, their body length
was indistinguishable from control embryos from the
same clutch (Figures 6A–6C). The phenotype was also spe-
cific; the observed pathology could be rescued efficiently
with co-injection of wild-type mouse full-length sec61a1
mRNA (100% identity between human and mouse at the
protein level; p ¼ 2.2 3 1016 between morphants and co-
injection with sbMO and wild-type message; Figures 6D
and 6E). Next, to test whether the variants identified in
the two pedigrees might be pathogenic, we co-injected
sec61al2 sbMO with the mouse sec61a1 mRNA harboring
the c.200T>G (p.Thr185Ala) or c.553A>G (p.Val67Gly)
variant and we scored for presence or absence of convolu-
tion of the pronephric tubules. Masked scoring at 4 dpfThe Ashowed that the mutant messages failed to rescue the
tubular atrophy phenotype driven by the sbMO. Embryos
co-injected with sbMO and c.553A>G (p.Thr185Ala) were
indistinguishable from morphants, suggesting a complete
loss of function of the c.553A>G (p.Thr185Ala) variant
(p ¼ 0.64, Figures 6D and 6E). The second variant,
c.200T>G (p.Val67Gly), was found to be a partial loss-of-
function allele: we observed a partial rescue of the pheno-
type in embryos co-injected with sbMO and (c.200T>G
[p.Val67Gly]; Figures 6D and 6E). To validate our MO-
deriveddata,wedesignedand testedguideRNAs togenerate
a sec61al2 CRISPR mutant. After validation of the guide
RNA efficiency and evaluation of the percentage of mosai-
cism in the F0 founders (50%; Figure S7), we stained the
pronephric tubules. We found that the F0 CRISPR mutants
fully recapitulated the morphants; we observed convolu-
tion defects including V-shaped and straight tubules in
55% of the F0 founders injected with guide RNA and Cas9
(Figure S7). Taken together, our functional data suggest
that SEC61A1 is necessary for the proper tubular organiza-
tion of the nephron and that variants in SEC61A1 found
in the two families are pathogenic.
Discussion
Here, we present evidence that mutations in SEC61A1with
complete or partial loss of function compared to wild-typemerican Journal of Human Genetics 99, 174–187, July 7, 2016 183
can cause autosomal-dominant progressive tubulo-inter-
stitial and glomerulocystic kidney disorder with anemia.
Combining linkage analysis with WES in one family, fol-
lowed by targeted testing and identification of a second
family with a similar phenotype, indicated that missense
mutations, predicted to affect the pore function of the
SEC61 translocon complex, segregate with the disorder
and are the likely drivers. Consistent with causality, one
of the discovered alleles was absent from 121,410 control
alleles, while the second was found only once. Notably,
SEC61A1 is evolutionarily conserved and intolerant to
deleterious variation in humans. There are no individuals
with truncating or nonsense mutations in the ExAC data-
base andmost of the 94 identified alleles carrying missense
variants represent changes that are structurally predicted
to be neutral.
To interrogate further the functional candidacy of the
discovered variants, we found that when expressed in
HEK293 cells, the wild-type protein localized exclusively
in the ER whereas both SEC6A1A variants are localized in
the ER and abnormally in the Golgi. These in vitro data
were then confirmed in kidney tissue from an affected in-
dividual. Taken together, this suggests that themutant pro-
teins probably do not interfere with translocons that are
formed by the remaining pool of wild-type proteins, but
rather they form translocons that are malfunctioning,
which causes disease. We also utilized zebrafish embryo
as an in vivo model. Consistent with our genetic and
in vitro findings, suppression of sec61a1 recapitulates the
tubular phenotype, while both discovered mutations
impede the ability of the protein to function. Of note,
the phenotype of the family bearing the functionally
determined null allele (c.553A>G [p.Thr185Ala]) appears
to have a more severe and more complex phenotype,
although caution is obviously warranted in extrapolating
genotype-phenotype correlations. The discovery of addi-
tional families with SEC61A1 mutations and the func-
tional stratification of new alleles will be necessary to test
this hypothesis. Likewise, we speculate that the SEC61A1
alleles probably contribute to some of the additional phe-
notypes (e.g., cognitive impairment, neutropenia) found
in the two families, though further laboratory investiga-
tion will be required to confirm this.
In contrast to the phenotype observed in the
Sec61a1Y344H/Y344H (GenBank: NM_016906.41) ENU-
inducedmouse homozygous for themutant allele at codon
344 encoding a histidine-to-tyrosine substitution,42 we did
not observe any glucose homeostasis or hepato-steatosis
problems in our affected individuals. To the best of our
knowledge, the renal tubular structures in homozygous
and heterozygous mice have not been investigated. This
discrepancy between phenotypic effects may be explained
by the structural mapping of the mutations. Mutations
described in our study affect directly the selectivity and
permeability of the pore of the translocon channel. This
implies that every translocon channel that contains the
mutated SEC61A1 subunit is dysfunctional; the mutations184 The American Journal of Human Genetics 99, 174–187, July 7, 20are therefore acting as complete or partial loss of function.
On the other hand, the recessive p.His344Tyr substitution
is located at the luminal helix, forming a patch for the
insertion of nascent peptides into membrane. Therefore,
we can speculate that this mutation should not alter trans-
locon pore functions per se. However, additional func-
tional experiments both in vitro and in vivo are required
to assess fully the pathogenicity of the p.His344Tyr substi-
tution in the context of the renal development.
The SEC61 complex is a major component of the
mammalian translocon, a complex that is needed to
transport newly synthesized secretory proteins into the
ER,43 integrate nascent proteins into membranes, and
maintain ER ion permeability barrier.44 Our study of the
structure of SEC61 translocon indicated that the two var-
iants have the potential to disrupt the function of translo-
con pore by affecting the integrity of the plug domain or
the constriction ring. We therefore speculate that altered
structural properties of SEC61A1 may destabilize the
translocon pore and lead to alterations in post-transla-
tional modifications, folding and sorting of various secre-
tory and transmembrane proteins, and/or alterations in
Ca2þ homeostasis. Such dysfunctions may induce ER
stress or prevent the cell from responding appropriately
to induced ER stress, with either ultimately leading to
apoptosis. Chronic ER stress is the major pathogenic
mechanism driving development and progression of
ADTKD caused by REN3 and UMOD mutations.45 Of
note, most identified REN mutations reduce the hydro-
phobicity of the signal peptide. Recent structural studies
of Sec61 complexed with signal peptide indicates that
aberrant interaction of the mutated signal peptides may
destabilize the opened SEC61 translocon pore during co-
translational translocation.46 This situation may therefore
represent a common pathogenetic mechanism leading to
similar clinical symptoms in affected individuals with
REN and SEC61A1 mutations. ER stress has been postu-
lated to play a mechanistic role in other disorders such
as diabetes and open angle glaucoma.47,48 Promising clin-
ical trial results indicate that the chemical chaperone so-
dium phenylbutyrate (BPA) is efficient on these diseases
and can alleviate the phenotypes in both mouse models
and humans.49,50 We therefore hypothesize that PBA
may provide therapeutic benefits in individuals with
SEC61A1 mutations and in other ER stress-related renal
diseases.
In conclusion, we report two deleterious mutations in
SEC61A1, a gene implicated in ADTKD. In light of previous
studies,51,52 our work provides additional evidence of the
importance of the translocon in the normal development
of the kidney.Supplemental Data
Supplemental Data include seven figures and one table and can be
found with this article online at http://dx.doi.org/10.1016/j.ajhg.
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